ArticleMolecular biology reports2026
Comparison of subcellular trafficking of the low molecular weight protamine (LMWP) fragment in tumor and non-tumor cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLow molecular weight protamines (LMWPs) are short polycationic peptides that have been utilized for cellular delivery of biodrugs and nucleic acids or as a part of nanopharmaceutical drug delivery systems. Despite the potential impact of LMWPs for biopharmaceutical applications, its intracellular trafficking in human cells is still not fully understood. In this study, we compared the cellular uptake efficiency, intracellular trafficking and subcellular localization of the LMWP (TDSP4) in various types of human tumor and non-tumor cell lines. METHODS AND
resultsOur findings demonstrate that the peptide could be rapidly internalized (within 15 min) in all tested cell lines. Also, time-lapse live-cell imaging experiments revealed that the peptide mainly traffics from the plasma membrane to the nuclear/nucleolar compartment, with a notable substantial time-dependent increase in the peptide-nuclear accumulation but at different rates based on the type of cells.
conclusionsAt the first time, LMWP peptide subcellular trafficking has been explored in tumor and non-tumor cell lines. This report provides an important preliminary understanding of the dynamic cellular trafficking of the LMWP which can help in the development of potential peptide-based therapeutics in the future.
Indexed as
Identifiers
41563624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.